{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:36:14Z","timestamp":1788726974829,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109367h0003"],"award-info":[{"award-number":["20ek0109367h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ek0109367h0002"],"award-info":[{"award-number":["19ek0109367h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1051"],"award-info":[{"award-number":["20FC1051"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016274","name":"Omron Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ahjo.2021.100053","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T19:29:21Z","timestamp":1634066961000},"page":"100053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction"],"prefix":"10.1016","volume":"11","author":[{"given":"Nobuyuki","family":"Enzan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouji","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Higo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2021.100053_bb0005","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"36","key":"10.1016\/j.ahjo.2021.100053_bb0015","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2021.100053_bb0020","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2020.13","article-title":"Heart failure with mid-range or recovered ejection fraction: differential determinants of transition","volume":"6","author":"Margonato","year":"2020","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.ahjo.2021.100053_bb0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ahjo.2021.100053_bb0030","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0035","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0040","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Lofman","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018719","article-title":"Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)","volume":"7","author":"Farre","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahjo.2021.100053_bb0050","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/ejhf.879","article-title":"Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction","volume":"19","author":"Rastogi","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","article-title":"Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes","volume":"9","author":"Nadruz","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. results of the cooperative north scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100053_bb0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2021.100053_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2021.100053_bb0075","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0080","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0085","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure Association of the European Society of cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010705","article-title":"Dilated cardiomyopathy with mid-range ejection fraction at diagnosis: characterization and natural history","volume":"8","author":"Gentile","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ahjo.2021.100053_bb0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1253\/circrep.CR-21-0001","article-title":"Clinical characteristics and contemporary management of patients with cardiomyopathies in Japan- report from a National Registry of clinical personal records","volume":"3","author":"Enzan","year":"2021","journal-title":"Circ. Rep."},{"key":"10.1016\/j.ahjo.2021.100053_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.ahjo.2021.100053_bb0105","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0110","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100053_bb0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jjcc.2013.10.014","article-title":"Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the japanese diastolic heart failure study (J-DHF)","volume":"63","author":"Yamamoto","year":"2014","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2021.100053_bb0125","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ahjo.2021.100053_bb0130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","article-title":"Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers","volume":"101","author":"Flannery","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0135","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.CIR.85.3.1046","article-title":"Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure","volume":"85","author":"Beuckelmann","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100053_bb0140","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2021.100053_bb0145","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2021.100053_bb0150","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2021.100053_bb0155","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCHEARTFAILURE.113.000813","article-title":"Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after \u03b2-blocker therapy","volume":"7","author":"de Groote","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0160","first-page":"e147","article-title":"Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy","volume":"25","author":"Moon","year":"2009","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100053_bb0165","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ehf2.12283","article-title":"Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis","volume":"5","author":"Lauritsen","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003123","article-title":"Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial","volume":"9","author":"Florea","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0175","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100053_bb0180","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lupon","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2021.100053_bb0185","first-page":"784","article-title":"Heart failure with mid-range ejection fraction - state of the art","volume":"112","author":"Mesquita","year":"2019","journal-title":"Arq. Bras. Cardiol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:52:49Z","timestamp":1778921569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602221000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":37,"alternative-id":["S2666602221000513"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100053","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100053"}}